Purified Human TL1A/TNFSF15 protein (N-His) on SDS-PAGE under reducing (P+) and non-reducing (P-) conditions. The purity of the purified protein appears to be greater than 95% based on reducing condition.
Cat #
Size
Price
Quantity
605701
25 ug
$145
605702
100 ug
$295
Product Details
Application
ELISA, BLI
Format
Liquid, Purified
Expression Host
CHO
Target Name
TNFSF15, TL1A, VEGI
Species
Human
accession number
O95150
Sources
Recombinant Human TNFSF15 (Leu72-Leu251) with N-terminus His tag is expressed in CHO cells.
Molecular Weight
This protein has a predicted molecular weight of 23 kDa. Under DTT-reducing conditions, the protein migrates at approximately 25-30 kDa on SDS-PAGE.
Affinity Tag
N-His
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
TNFSF15 (also known as VEGI or TL1A) is a member of the tumor necrosis factor (TNF) ligand superfamily. It is predominantly produced by endothelial cells and certain immune cells. TNFSF15 plays important roles in controlling immune regulation, inflammation, and the formation of new blood vessels (angiogenesis). By engaging its receptor DR3 (Death Receptor 3), it can trigger programmed cell death (apoptosis) and influence T cell activation and differentiation. Due to its involvement in autoimmune diseases, inflammatory conditions, and cancer, TNFSF15 is considered a promising target for therapeutic intervention.
Purified Human TL1A/TNFSF15 protein (N-His) on SDS-PAGE under reducing (P+) and non-reducing (P-) conditions. The purity of the purified protein appears to be greater than 95% based on reducing condition.
